Cargando…

Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy

BACKGROUND: The Spectrum projection package uses estimates of national HIV incidence, demographic data and other assumptions to describe the consequences of the HIV epidemic in low and middle-income countries. The default parameters used in Spectrum are updated every 2 years as new evidence becomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahy, Mary, Lewden, Charlotte, Brinkhof, Martin W G, Dabis, Francois, Tassie, Jean-Michel, Souteyrand, Yves, Stover, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173808/
https://www.ncbi.nlm.nih.gov/pubmed/21106512
http://dx.doi.org/10.1136/sti.2010.044255
_version_ 1782211997740302336
author Mahy, Mary
Lewden, Charlotte
Brinkhof, Martin W G
Dabis, Francois
Tassie, Jean-Michel
Souteyrand, Yves
Stover, John
author_facet Mahy, Mary
Lewden, Charlotte
Brinkhof, Martin W G
Dabis, Francois
Tassie, Jean-Michel
Souteyrand, Yves
Stover, John
author_sort Mahy, Mary
collection PubMed
description BACKGROUND: The Spectrum projection package uses estimates of national HIV incidence, demographic data and other assumptions to describe the consequences of the HIV epidemic in low and middle-income countries. The default parameters used in Spectrum are updated every 2 years as new evidence becomes available to inform the model. This paper reviews the default parameters that define the course of HIV progression among adults and children in Spectrum. METHODS: For adults, data available from published and grey literature and data from the ART-LINC International epidemiologic Database to Evaluate AIDS (IeDEA) collaboration were combined to estimate survival among those who started antiretroviral therapy (ART). For children, a review of published material on survival on ART and survival on ART and cotrimoxazole was used to derive survival probabilities. Historical data on the distribution of CD4 cell counts and CD4 cell percentages by age among children who were not treated (before treatment was available) were used to progress children from seroconversion to different CD4 cell levels. RESULTS: Based on the updated evidence estimated survival among adults aged over 15 years in the first year on ART was 86%, while in subsequent years survival was estimated at 90%. Survival among children during the first year on ART was estimated to be 85% and for subsequent years 93%. DISCUSSION: The revised default parameters based on additional data will make Spectrum estimates more accurate than previous rounds of estimates.
format Online
Article
Text
id pubmed-3173808
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BMJ Group
record_format MEDLINE/PubMed
spelling pubmed-31738082011-09-23 Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy Mahy, Mary Lewden, Charlotte Brinkhof, Martin W G Dabis, Francois Tassie, Jean-Michel Souteyrand, Yves Stover, John Sex Transm Infect Supplement BACKGROUND: The Spectrum projection package uses estimates of national HIV incidence, demographic data and other assumptions to describe the consequences of the HIV epidemic in low and middle-income countries. The default parameters used in Spectrum are updated every 2 years as new evidence becomes available to inform the model. This paper reviews the default parameters that define the course of HIV progression among adults and children in Spectrum. METHODS: For adults, data available from published and grey literature and data from the ART-LINC International epidemiologic Database to Evaluate AIDS (IeDEA) collaboration were combined to estimate survival among those who started antiretroviral therapy (ART). For children, a review of published material on survival on ART and survival on ART and cotrimoxazole was used to derive survival probabilities. Historical data on the distribution of CD4 cell counts and CD4 cell percentages by age among children who were not treated (before treatment was available) were used to progress children from seroconversion to different CD4 cell levels. RESULTS: Based on the updated evidence estimated survival among adults aged over 15 years in the first year on ART was 86%, while in subsequent years survival was estimated at 90%. Survival among children during the first year on ART was estimated to be 85% and for subsequent years 93%. DISCUSSION: The revised default parameters based on additional data will make Spectrum estimates more accurate than previous rounds of estimates. BMJ Group 2010-11-23 2010-12 /pmc/articles/PMC3173808/ /pubmed/21106512 http://dx.doi.org/10.1136/sti.2010.044255 Text en © 2010, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
spellingShingle Supplement
Mahy, Mary
Lewden, Charlotte
Brinkhof, Martin W G
Dabis, Francois
Tassie, Jean-Michel
Souteyrand, Yves
Stover, John
Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy
title Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy
title_full Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy
title_fullStr Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy
title_full_unstemmed Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy
title_short Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy
title_sort derivation of parameters used in spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy
topic Supplement
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173808/
https://www.ncbi.nlm.nih.gov/pubmed/21106512
http://dx.doi.org/10.1136/sti.2010.044255
work_keys_str_mv AT mahymary derivationofparametersusedinspectrumforeligibilityforantiretroviraltherapyandsurvivalonantiretroviraltherapy
AT lewdencharlotte derivationofparametersusedinspectrumforeligibilityforantiretroviraltherapyandsurvivalonantiretroviraltherapy
AT brinkhofmartinwg derivationofparametersusedinspectrumforeligibilityforantiretroviraltherapyandsurvivalonantiretroviraltherapy
AT dabisfrancois derivationofparametersusedinspectrumforeligibilityforantiretroviraltherapyandsurvivalonantiretroviraltherapy
AT tassiejeanmichel derivationofparametersusedinspectrumforeligibilityforantiretroviraltherapyandsurvivalonantiretroviraltherapy
AT souteyrandyves derivationofparametersusedinspectrumforeligibilityforantiretroviraltherapyandsurvivalonantiretroviraltherapy
AT stoverjohn derivationofparametersusedinspectrumforeligibilityforantiretroviraltherapyandsurvivalonantiretroviraltherapy